KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,034 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the sale, the chief executive officer owned 442,883 shares of the company’s stock, valued at $6,895,688.31. This trade represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded up $0.21 during midday trading on Tuesday, reaching $15.77. 751,567 shares of the company’s stock were exchanged, compared to its average volume of 635,299. The stock’s 50-day simple moving average is $15.47 and its 200 day simple moving average is $13.94. The firm has a market cap of $797.17 million, a price-to-earnings ratio of -3.99 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.00.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KALV. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Needham & Company LLC boosted their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Citizens Jmp lowered their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Finally, HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $57,000. KLP Kapitalforvaltning AS acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $63,000. Finally, Truvestments Capital LLC lifted its holdings in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.